AGPG engaged in a physical interaction with PURα, which in turn freed E2F1 from PURα’s grasp, thereby triggering the activation of E2F1 signaling pathways in ERα-positive breast cancer cells. The gene discussed is E2F1; the disease is breast carcinoma.